Aniracetam
Aniracetam scored 6.4 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Racetam.
Aniracetam is mainly a creativity and verbal-fluency experiment, with historical dosing around 750-1,500 mg/day and human evidence concentrated in older cognitive-disorder literature such as Sourander 1987. The anxiolytic story is interesting but still thin for healthy users.
What is Aniracetam?
Aniracetam scores 5.1/10 because its strongest case is cognition, memory, and anxiety-adjacent mechanisms, with weaker support outside that lane. The best read is practical and narrow: match the intervention to readers evaluating racetam-style cognitive support rather than systemic health claims.
The main evidence anchor is Gouliaev and Senning 1994. Nakamura et al. 2001 adds important context, while Cohen et al. 2021 helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that human evidence is older and mostly disease-oriented, while current supplement supply quality is uneven. This report treats Aniracetam as a candidate for specific use cases, not a general wellness shortcut.
Terminology
- AMPA receptor: A fast glutamate receptor that handles most quick excitatory signaling between neurons. Aniracetam fine tunes how long these signals last.
- Positive allosteric modulator: A compound that does not switch a receptor on by itself but boosts the receptor's response when its natural signal arrives. This is how aniracetam works on AMPA receptors.
- Racetam: The family of synthetic nootropics built around a pyrrolidone ring. Piracetam was first, and aniracetam is a fat soluble cousin.
- Anxiolytic: Anxiety reducing. Aniracetam shows this effect in animal anxiety models.
- Fat soluble: Absorbs better when taken with dietary fat. This is why aniracetam is usually dosed with a meal or an oil.
- Nootropic: A substance studied for cognitive support like memory, focus, or verbal fluency.
- NOAEL: No observed adverse effect level. The highest dose in a toxicology study that produced no harm, used to set safety margins.
How do you take Aniracetam?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 750-1,500 mg/day in historical and anecdotal use, often with food because it is fat-soluble | 750-1,500 mg/day in historical and anecdotal use, often with food because it is fat-soluble |
Protocols
Conservative research comparison Mixed
- Dose
- 750-1,500 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
What are the benefits of Aniracetam?
Upside contribution: 1.91
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.9 | 0.725 | |
| Breadth | 15% | 3.0 | 0.450 | |
| Evidence | 25% | 3.6 | 0.900 | |
| Speed | 10% | 2.6 | 0.260 | |
| Durability | 10% | 1.8 | 0.180 | |
| Bioindividuality | 15% | 2.6 | 0.390 | |
| Total | 2.905 |
Upside Rationale
Aniracetam's upside is concentrated in cognition, memory, and anxiety-adjacent mechanisms. The literature is older and pharmacology-led rather than built on modern healthy-adult trials, but it is more substantial than a single study, so the rating rewards the specific use cases while staying conservative about claims beyond them.
Efficacy (2.9/5.0): Aniracetam earns a near-median efficacy score because the best signals map to cognition, memory, and anxiety-adjacent mechanisms, mostly in older clinical and pharmacology work rather than healthy-adult replication. Gouliaev and Senning 1994 is the main anchor, while Nakamura et al. 2001 helps define where the signal remains preliminary.
Breadth of Benefits (3.0/5.0): Aniracetam has moderate breadth around its core lane of memory, cognition, and anxiety-adjacent effects, with AMPA-modulation and cholinergic mechanisms supporting more than one plausible benefit. The report gives credit where the evidence matches readers evaluating racetam-style cognitive support, and less where endpoints drift into unrelated systems.
Evidence Quality (3.6/5.0): Aniracetam has a real, if dated, evidence base: a substantial pharmacology and clinical literature reviewed in Gouliaev and Senning 1994, plus mechanistic and dementia-context studies, and modern supplement-market scrutiny in Cohen et al. 2021. The score is above median because the mechanism and historical clinical use are well documented, while staying short of the top because the work is old, sponsor-concentrated, and lacks current healthy-adult replication.
Speed of Onset (2.6/5.0): Aniracetam can produce faster feedback when the intended effect is acute attention or subjective cognitive lift, since it is short-acting and fat-soluble. That speed helps users judge fit, but it does not replace longer follow-up, and the subjective signal can be hard to separate from expectation.
Durability (1.8/5.0): Aniracetam durability is low. It is short-acting, effects depend on continued dosing, and there is no evidence of a lasting cognitive change after stopping. The score rises only when a benefit can be maintained without dose escalation, which the literature does not establish.
Bioindividuality Upside (2.6/5.0): Aniracetam has meaningful bioindividuality because baseline need, medications, caffeine response, training status, liver or bile context, sleep pressure, and tolerance can change the outcome. Nakamura et al. 2001 is useful for defining that context.
What are the risks & downsides of Aniracetam?
Downside contribution: 0.80 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.6 | 0.480 | |
| Side effects | 15% | 1.6 | 0.240 | |
| Cost | 5% | 2.4 | 0.120 | |
| Effort | 5% | 1.6 | 0.080 | |
| Opportunity | 5% | 2.2 | 0.110 | |
| Dependency | 15% | 1.4 | 0.210 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.615 | |||
| Harm subtotal × 1.4 | 1.827 | |||
| Opportunity subtotal × 1.0 | 0.310 | |||
| Combined downside | 2.137 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.797 |
Downside Rationale
Aniracetam downside is driven by an evidence base that is older and mostly disease-oriented, paired with uneven current supplement supply quality. The risk score is highest where user selection, product quality, stimulant load, medical context, or regulation can change the expected result.
Safety (1.6/5.0): Aniracetam's intrinsic safety profile is benign in the documented literature, with no serious toxicity signal at typical doses; the practical concerns are dose, diagnosis, medication use, and source quality rather than demonstrated harm. Nakamura et al. 2001 is the main safety anchor for this dimension.
Side Effects (1.6/5.0): Aniracetam side effects are generally mild and reversible, things like headache, mild GI upset, jitteriness, or sleep disruption, and they matter mostly because the likely use cases depend on subjective feel. Gouliaev and Senning 1994 helps frame expected benefits against tolerability.
Interaction Risk (2.0/5.0): Aniracetam interaction risk rises when users combine it with stimulants, sedatives, anticoagulants, liver-active agents, training stress, or disease-specific treatment. The report keeps this dimension separate from general safety.
Supply (3.0/5.0): Aniracetam supply risk reflects labeling accuracy, adulteration, ingredient identity, and whether the market is supplement, prescription, peptide, or gray-market dominated. Cohen et al. 2021 is especially relevant when product trust is part of the risk.
Cost (2.4/5.0): Aniracetam cost risk is not only price per serving. It also includes the cost of chasing weak evidence, lab testing, medical monitoring, or replacing simpler options such as sleep, diet, training, or caffeine management.
Regulatory (2.7/5.0): Aniracetam regulatory risk depends on whether the compound is a normal food, a dietary supplement ingredient, a drug, a sport-restricted substance, or a research peptide. This can be the deciding downside for athletes and cautious users.
Bioindividuality Downside (2.4/5.0): Aniracetam bioindividuality downside is meaningful because personal risk can swing with anxiety, sleep timing, pregnancy, age, liver or kidney status, sport testing, CYP metabolism, and baseline deficiency or excess.
Is Aniracetam worth it?
Aniracetam earns a 6.4 because its strongest case is narrow and real: a fat soluble racetam that fine tunes AMPA receptors and is studied for memory, verbal fluency, and connecting ideas, with a mild anxiety reducing feel on top. The catch is that most human evidence is older and aimed at cognitive decline, and supplement supply quality is uneven, so the upside is plausible but not locked in for healthy users.
✅ Best for: Readers who want a creativity and verbal fluency leaning nootropic, take it with food, run it in cycles with breaks, buy from a vendor with third party purity testing, and track one concrete cognitive target so they can tell if it actually helps.
❌ Avoid if: You are pregnant or nursing, have serious liver or organ disease, take interacting medications, face athlete drug testing, or are stimulant sensitive. Skip it too if your goal is general all day optimization that better studied basics like sleep, training, and nutrition already cover.
What is Aniracetam best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 5.0/10
Score: 5.0/10Aniracetam scores 5.0/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Aniracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Memory: 5.0/10
Score: 5.0/10Aniracetam scores 5.0/10 for memory because the most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Aniracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Anxiety: 5.0/10
Score: 5.0/10Aniracetam scores 5.0/10 for anxiety because the most cited anxiolytic case rests on animal and mechanism work rather than human anxiety trials. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Aniracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does aniracetam actually do?
Aniracetam is a fat soluble racetam that fine tunes AMPA receptors, the fast glutamate receptors your brain uses for quick signaling. By slowing how fast those signals fade, it is studied for memory, verbal fluency, and connecting ideas, and it also shows anxiety reducing effects in animal models per Nakamura and Kurasawa 2001. Most human work is older and aimed at cognitive decline, so treat it as cognitive support, not a cure.
How much aniracetam should I take and how?
Community and older clinical use centers on roughly 750 to 1,500 mg per day, often split into two doses. Because aniracetam is fat soluble, take it with a meal or a fat source so it absorbs well. Start at the low end, see how you respond, and avoid stacking it with several overlapping stimulants at once. Higher doses are a separate risk decision, not a default.
Does aniracetam actually improve memory in people?
The human evidence is real but dated and mostly disease oriented. Early trials like Sourander et al. 1987 tested it in Alzheimer type dementia, and reviews such as Lee and Benfield 1994 summarize cognitive benefits in older adults with impairment. There is little modern, placebo controlled work in healthy people, so the memory case is suggestive rather than proven for everyday users.
Is aniracetam safe to take long term?
Short term tolerability in trials looks reasonable, and animal toxicology established a usable safety margin per Ogiso et al. 1998 on how it is processed. The honest gap is that long human follow up is thin, and aniracetam is not an approved supplement ingredient in the United States. I treat it as a cycled tool with breaks, not a daily standing habit, until better long term data exists.
Who should not take aniracetam?
Skip aniracetam if you are pregnant or nursing, have a serious liver or organ condition, or take medications that could interact, since the human safety record is limited. Athletes should check their sport's rules before using any nootropic. If you are sensitive to stimulating compounds or your only goal is vague all day optimization, better studied basics will serve you more reliably.
How fast does aniracetam work?
Because it is fat soluble, aniracetam absorbs and clears fairly quickly, so many users notice subtle same day effects on focus or verbal flow within an hour or two of a dose with food. The clearer way to judge it is to pick one concrete target ahead of time, like word recall or task switching, and check it across a short trial rather than relying on a vague feeling of being sharper.
How does aniracetam compare to other racetams like piracetam?
Aniracetam is fat soluble and tends to feel more relaxing and creativity oriented, while piracetam is water soluble and often described as more neutral. Both sit in the same pyrrolidone family covered by Malykh and Sadaie 2010. Piracetam has more total human research, so if you want the better studied option, it may be the safer starting point before reaching for aniracetam.
Is aniracetam sold as a clean, legitimate supplement?
Quality is a real concern. Aniracetam is an unapproved drug in the United States, so it is sold as a research chemical or gray market supplement with uneven purity. Cohen et al. 2021 found unapproved drugs in products marketed for cognitive enhancement. If you choose to use it, buy from a vendor that publishes third party certificates of analysis confirming identity and purity.
What could change Aniracetam's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Aniracetam could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Aniracetam could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 6.3 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 5.1 / 10 ⚖️ Neutral |
| New safety, sourcing, regulatory, or replication concerns appear. | 3.9 / 10 ⚠️ Caution |
BioHarmony Engine v2.0
Key Evidence Sources
- Lee and Benfield 1994 - Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders, Drugs & Aging. A review of aniracetam's pharmacology and its cognitive benefits in older adults with senile cognitive disorders.
- Nakamura 2002 - Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries, CNS Drug Reviews. A pharmacology review proposing aniracetam's therapeutic potential across cerebral dysfunction based on its receptor effects.
- Isaacson and Nicoll 1991 - Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus, Proceedings of the National Academy of Sciences. Mechanistic work showing aniracetam reduces AMPA receptor desensitization and prolongs fast excitatory signaling in the hippocampus.
- Nakamura and Kurasawa 2001 - Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism, European Journal of Pharmacology. Animal study reporting anxiety reducing effects of aniracetam across three mouse anxiety models and the mechanisms behind them.
- Cumin et al. 1982 - Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents, Psychopharmacology. Early rodent study showing aniracetam improved impaired learning and memory across several behavioral tasks.
- Sourander et al. 1987 - Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent, Psychopharmacology. A clinical trial testing aniracetam as a nootropic in patients with Alzheimer type senile dementia.
- Ogiso et al. 1998 - Pharmacokinetics of aniracetam and its metabolites in rats, Journal of Pharmaceutical Sciences. Pharmacokinetic study mapping how aniracetam and its metabolites are absorbed and processed in rats.
- Malykh and Sadaie 2010 - Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders, Drugs. A broad review of the racetam family covering mechanisms and clinical applications across central nervous system disorders.
- Cohen et al. 2021 - Five Unapproved Drugs Found in Cognitive Enhancement Supplements, Neurology Clinical Practice. An analysis that detected five unapproved drugs in products sold as cognitive enhancement supplements, underscoring supply quality risk.
What does the evidence say about Aniracetam?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Lee and Benfield 1994, Nakamura 2002, Isaacson and Nicoll 1991, Nakamura and Kurasawa 2001, Cumin et al. 1982, Sourander et al. 1987, Cohen et al. 2021
Pre-RCT-Era Pharmacology and Use
Citations: Malykh and Sadaie 2010
Traditional Medicine Systems
Citations: Lee and Benfield 1994
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Sleep Duration During | Expected Watch
- Mood Score During | Expected Watch
Pulse Dimensions to Watch
- Calm During | Expected Up | Primary
- Drive During | Expected Up | Secondary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Social Ease Scale 1-5 | During | Expected Up
- Headache Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Worsening anxiety, agitation, or insomnia
- Unknown-source product or mislabeled capsules
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.905 − 0.797 = 1.108
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.108 / 4.00) × 5 = 6.4 / 10
Further learning
65+ Nootropic Ingredients I’ve Supplemented (Rated & Reviewed)
I've tested all kinds of nootropic ingredients & brain-boosting supplements. Here's a simple rundown, my personal ratings and mini review, and practical uses of…
Unconventional Ways to Power Up Your Brain & Perform Like an Elite Athlete
Did you know you could optimize your brain & body performance using nootropics safely & effectively? We discuss using substances like caffeine, dynamine &…
